Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluvastatin + fenofibrate versus simvastatin + ezetimibe crossover study in metabolic syndrome
2006-002007-13Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fluvastatin, fenofibrate, simvastatin and ezetimibe in lipid disorder and cardiometabolic risk (CMR) (2 arms), sponsored by Novartis. Primary endpoint: High-density lipoprotein cholesterol. Started Apr 2006; status: completed.
02
Drugs
fluvastatinfenofibratesimvastatinezetimibe
03
Conditions
lipid disordercardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2006-002007-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002007-13.